FFO
RNA

Fortitude Family Office’s Atrium Therapeutics RNA Stock Holding History

Fortitude Family Office’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673 Buy
+50
New +$653 ﹤0.01% 1895

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Fortitude Family Office's RNA Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 50 shares worth $673. The stake represents ﹤0.01% of the portfolio and ranks #1895 among its holdings.

19 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Fortitude Family Office held 50 shares of Atrium Therapeutics worth $673 as of Q2 2026.
  • Atrium Therapeutics was a new Fortitude Family Office position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1895 holding.
  • 19 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.